← All trials
NCT03718494
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 30, 2019
- Primary completion
- Jun 30, 2022
- Completion date
- Jun 30, 2022
- First posted
- —
- Last posted
- —
- Enrollment
- 688
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Mayo ClinicLead sponsor
- University of ArizonaCollaborator
- Harvard UniversityCollaborator
- Yale UniversityCollaborator
- University of California, San FranciscoCollaborator
- Mayo ClinicReponsible party - principal investigator
- Columbia UniversityCollaborator
- National Institute on Aging (NIA)Collaborator
- Utah State UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.